Results 81 to 90 of about 152,178 (350)

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis

BMC Cancer
Objective This study aimed to evaluate the efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer using a network meta-analysis approach.
Chaoyang Wang, Dong Xiao, Chao Zhai
doaj   +1 more source

JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12

Cell Death Discovery, 2021
Breast cancer is the most common cancer worldwide. JWA is a microtubule-associated protein that has been identified as a tumor suppressor, and its downregulation in tumors is an independent adverse prognostic factor.
Yan Liang, Chao Qian, Yinghong Xie, Xiang Huang, Junjie Chen, Yanlin Ren, Ziyi Fu, Yongfei Li, Tianyu Zeng, Fan Yang, Jianwei Zhou, Wei Li, Yongmei Yin, Changqing Wang   +13 more
doaj   +1 more source

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Nature Medicine
Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated efficacy and safety analyses, including secondary and exploratory efficacy
J. Cortés, S. Hurvitz, Seock-Ah Im, H. Iwata, G. Curigliano, Sung-Bae Kim, Joanne W. Y. Chiu, J. Pedrini, Wei Li, K. Yonemori, G. Bianchini, S. Loi, G. Borges, Xian Wang, T. Bachelot, Shunsuke Nakatani, S. Ashfaque, Zhengkang Liang, A. Egorov, E. Hamilton   +19 more
semanticscholar   +1 more source

Development of Endogenous Protein Probes for Characterizing Surface Proteins and Cellular Interactors of Extracellular Vesicles

Advanced Science, EarlyView.
The proximity labeling enzyme APEX2 is displayed on extracellular vesicle (EV) surfaces via genetic fusion with EV‐sorting scaffolds, enabling in situ biotinylation of native surface proteins, adsorbed corona components, and interacting cellular proteins.
Wenyi Zheng, Metoboroghene Mowoe, Wenqing Hou, Daniel W. Hagey, Koshi Imami, Samir EL Andaloussi   +5 more
wiley   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S., Carideo, Luciano, Galli, Filippo, Lauri, Chiara, Pacilio, Massimiliano, Signore, Alberto, Valabrega, Stefano   +6 more
core   +2 more sources

Bacteriophage‐Mimetic DNA Origami Needle for Targeted Membrane Penetration and Cytosolic Cargo Delivery

Advanced Science, EarlyView.
We designed a synthetic DNA origami needle‐like structure inspired by bacteriophages for targeted drug delivery. Functionalized with trastuzumab antibodies, cholesterol, and dyes, it selectively targets SKBR3 cancer cells. A glutathione‐triggered dye payload enables controlled release, and delivery is verified using confocal microscopy and live cell ...
Anirban Samanta, Mette Galsgaard Malle, Emily Tsang, Marjan Omer, Mads K. Skaanning, Sarah Youssef, Jørgen Kjems, Kurt V. Gothelf   +7 more
wiley   +1 more source

Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models. [PDF]

, 2015
We have previously developed mouse models of HER-2-positive cervical cancer. Tumors in nude mice had histological structures similar to the original tumor and were stained by anti-HER-2 antibody in the same pattern as the patient's cancer.
Bouvet, Michael, Chishima, Takashi, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Ichikawa, Yasushi, Maawy, Ali, Matsuyama, Ryusei, Mii, Sumiyuki, Miwa, Shinji, Momiyama, Masashi, Mori, Ryutaro, Murakami, Takashi, Tanaka, Kuniya, Uehara, Fuminari, Yamamoto, Mako, Yano, Shuya, Zhang, Nan, Zhang, Yong, Zhao, Ming   +19 more
core   +7 more sources

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Health Technology Assessment, 2020
Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months’ trastuzumab, tested in
Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn   +26 more
doaj   +1 more source

Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy [PDF]

, 2014
Background: After breast-conserving radiation therapy most patients experience acute skin toxicity to some degree. This may impair patients' quality of life, cause pain and discomfort. In this study, we investigated treatment and patient-related factors,
De Langhe, Sofie, De Neve, Wilfried, De Ruyck, Kim, DE SCHEPPER, ELINE, Gilsoul, Monique, MULLIEZ, THOMAS, Remouchamps, Vincent, Thierens, Hubert, van Greveling, Annick, Veldeman, Liv   +9 more
core   +2 more sources